MorphoSys AG

Type: Company
Name: MorphoSys AG
Nationality: Germany
Web Address: http://www.morphosys.com/
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

MorphoSys gets funding for GPCR projects

MorphoSys AG has received grant funding for up to €1 million from the German Federal Ministry of Education and Research to support development of antibodies against two undisclosed G protein-coupled receptors (GPCRs) . The two-year grant will cover the ... [Published MedNous - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 1 reports

MorphoSys gets €1 mn grant from BMBF to develop novel therapeutics antibodies targeting GPCRs

MorphoSys AG, a leading biotechnology company, announced the receipt of a grant of up to EUR 1 million from the German Federal Ministry of Education and Research (BMBF), comprising funding for two of its therapeutic antibody programmes. The funding will ... [Published PharmaBiz - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 3 reports

MorphoSys Receives Research Grant to Develop Novel Therapeutic Antibodies Targeting GPCRs

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today the receipt of a grant of up to EUR 1 million from the German Federal Ministry of Education and Research (BMBF), comprising funding for two of its therapeutic antibody ... [Published Value Investing News - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

BRIEF-Morphosys says gets grant of up to 1 mln EUR from the German ministry

Sept 15 (Reuters) - Morphosys AG :* Says gets grant of up to 1 million EUR from the Germanministry of research to fund therapeutic antibody programSource text for Eikon ... [Published Reuters UK - Sep 15 2014]
Entities: MorphoSys AG, Antibody
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Hogan Lovells advises MorphoSys on cooperation with Emergent BioSolutions

MorphoSys, a TecDax listed company, has announced a licensing agreement with Emergent BioSolutions for the joint development and commercialization of the drug candidate ES414 targeting prostate cancer. The compound ES414, to be renamed MOR209/ES414, was ... [Published Hogan Lovells - Sep 12 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Merck KGaA dives into allergy R&D with platform pact

Facing dwindling sales and a thin late-stage pipeline, Merck KGaA is looking to accelerate its efforts in allergy drug development, signing a deal with an Austrian biotech with hopes of quickly seeding new programs in the field.The German drugmaker is ... [Published FierceBiotech - Sep 05 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

MorphoSys to Present at Six Investor Conferences in September

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following investor conferences in September ... [Published Value Investing News - Sep 04 2014]
Entities: MorphoSys AG, TecDAX
First reported Sep 02 2014 - Updated Sep 03 2014 - 1 reports

Emergent BioSolutions and MorphoSys partner to develop prostate cancer drug

Emergent BioSolutions Inc., a biopharmaceutical company, and MorphoSys AG have entered into an agreement to jointly develop and commercialize Emergent's preclinical bi-specific antibody, ES414, targeting prostate cancer. Under the terms of the agreement, ... [Published Individual.com - Sep 02 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Emergent And MorphoSys To Co-Develop Prostate Cancer Drug

By Estel Grace MasangkayEmergent BioSolutions announced that it has signed an agreement with therapeutic antibody specialist firm MorphoSys to co-develop and commercialize its preclinical bi-specific antibody ES414 as treatment for prostate cancer.ES414 ... [Published Bioresearch Online - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Morphosys bags antibody

Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.Related Biotechnology, Pharmaceutical ... [Published BioPortfolio - Aug 25 2014]
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

Emergent BioSolutions, MorphoSys ink agreement for ES414

Emergent BioSolutions , a Rockville, Md.-based global specialty biopharmaceutical company, and MorphoSys , a Germany-based provider of therapeutic antibodies, have inked an agreement for the joint development and commercialization of Emergent’s preclinical ... [Published Center Watch - Aug 23 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 28 reports

Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate

Emergent BioSolutions ( EBS ) inked a deal with MorphoSys, a German biotech company, to co-develop and subsequently market the former’s prostrate cancer candidate ES414 (MOR209/ES414 going forward). The candidate, an antibody to combat prostate cancer, ... [Published Yahoo! Finance - Aug 20 2014]

Quotes

technology " as part of the inaugural " Advances in Drug Discovery and Development " virtual symposium run by Chemical & Engineering News, a publication of the American Chemical Society. The virtual symposium is on Wednesday, 24 September 2014 ; Dr Marshall's presentation will take place at 2:00pm Eastern Daylight Time and can be viewed live by clicking here and will be available on http://www.heptares.com afterwards. Registration is required."
"We are delighted to receive this valuable support from the German government. Our Ylanthia platform is the perfect fit for therapeutic antibody discovery, especially against technically challenging targets. By applying our antibody capabilities to the discovery of novel therapeutics against GPCRs, we are opening up a whole range of new product opportunities" commented Dr. Marlies Sproll, chief scientific officer of MorphoSys AG
...available to develop new therapeutic forms for the most significant allergens, such as dust mites and pollen," Linari said in a statement. "We will now be working very hard on the further development of the active ingredients based on the licensed technology platform."

More Content

All (89) | News (61) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (20)
sort by: Date | Relevance
MorphoSys gets funding for GPCR projects [Published MedNous - Sep 17 2014]
Heptares to Present on Structure-Based Drug Des... [Published Market Pulse Navigator - Sep 16 2014]
MorphoSys gets €1 mn grant from BMBF to develop... [Published PharmaBiz - Sep 16 2014]
MorphoSys Receives Research Grant to Develop No... [Published Value Investing News - Sep 15 2014]
MorphoSys Receives Research Grant to Develop No... [Published ACN Newswire - Sep 15 2014]
MorphoSys Receives Research Grant to Develop No... [Published GlobeNewswire: Advertising News - Sep 15 2014]
BRIEF-Morphosys says gets grant of up to 1 mln ... [Published Reuters UK - Sep 15 2014]
MorphoSys Receives Research Grant to Develop No... [Published SPi World News - Sep 15 2014]
Hogan Lovells advises MorphoSys on cooperation ... [Published Hogan Lovells - Sep 12 2014]
Heptares To Present At [Published BioSpace - Sep 10 2014]
Heptares to Present at CNS Partnering & Deal-ma... [Published Myrtle Beach Sun News - Sep 10 2014]
Merck KGaA dives into allergy R&D with platform... [Published FierceBiotech - Sep 05 2014]
MorphoSys to Present at Six Investor Conference... [Published Value Investing News - Sep 04 2014]
MorphoSys to Present at Six Investor Conference... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
Emergent BioSolutions and MorphoSys partner to ... [Published Individual.com - Sep 02 2014]
Q3/2014 Quarterly Review [Published Noodls - Aug 26 2014]
Emergent And MorphoSys To Co-Develop Prostate C... [Published Bioresearch Online - Aug 26 2014]
Morphosys bags antibody [Published BioPortfolio - Aug 25 2014]
Emergent BioSolutions, MorphoSys ink agreement ... [Published Center Watch - Aug 23 2014]
Emergent BioSolutions MorphoSys ink agreement f... [Published BioPortfolio - Aug 22 2014]
MorphoSys, Emergent BioSolutions to advance pro... [Published Drug Discovery News - Aug 22 2014]
AZ may be too expensive for Pfizer, Orexo to up... [Published FierceBiotech - Aug 21 2014]
West Coast Biotech Roundup: Ebola, Mapp, Tekmir... [Published Xconomy - Aug 21 2014]
Emergent BioSolutions sign a biotech licensing ... [Published BioPortfolio - Aug 21 2014]
Emergent BioSolutions signs license agreement w... [Published BioPrepWatch - Aug 21 2014]
Emergent MorphoSys Collaborate on Prostate Canc... [Published BioPortfolio - Aug 21 2014]
Lilly joins the list of Enbrel-beaters with hea... [Published FierceBiotech - Aug 21 2014]
MorphoSys, Emergent BioSolutions to co-develop ... [Published PBR - News - Aug 21 2014]
Emergent BioSolutions, MorphoSys Tie Up on Canc... [Published Yahoo! Finance - Aug 20 2014]
BioNews [8.20.14] [Published eClinical Trends - Aug 20 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
MorphoSys, Emergent BioSolutions to co-develop ... [Published PBR - News - Aug 21 2014]
MorphoSys AG and Emergent BioSolutions Inc. announced an agreement for the joint development and commercialization of ES414. ...
BioNews [8.20.14] [Published eClinical Trends - Aug 20 2014]
Top News HeadlineCompanyType Emergent BioSolutions, MorphoSys AG Strike Prostate Cancer Pact Worth $183 Million Emergent BioSolutions & MorphoSys AGJoint development AstraZeneca's new antibiotic comes through in Phase III AstraZenecaPositive ...
Emergent BioSolutions and MorphoSys Sign Licens... [Published Business Wire Health News - Aug 19 2014]
ROCKVILLE, Md. & MUNICH & MARTINSRIED, Germany--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) today announced an agreement for the joint development and commercialization ...
MorphoSys gets additional patents on Ylanthia i... [Published PBR - News - Jul 21 2014]
MorphoSys has announced that the US Patent and Trademark Office (USPTO) and the State Intellectual Property Office of China have granted additional patents covering the Company's latest antibody platform Ylanthia. ...
MorphoSys, Merck Serono to develop new therapeu... [Published PBR - News - Jun 13 2014]
MorphoSys and Merck have signed co-development and license agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints. ...
1 2

Press Releases

sort by: Date | Relevance
MorphoSys Receives Research Grant to Develop No... [Published GlobeNewswire: Advertising News - Sep 15 2014]
MorphoSys to Present at Six Investor Conference... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
MorphoSys to Host Conference Call on License Ag... [Published GlobeNewswire: Advertising News - Aug 20 2014]
MorphoSys and Emergent BioSolutions Sign Licens... [Published GlobeNewswire: Advertising News - Aug 19 2014]
MorphoSys Provides Update on the Company's Prop... [Published GlobeNewswire: Defense News - Jul 28 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.